SG11201609248WA - Nox inhibitor and nfκb inhibitor containing methoxyflavone - Google Patents
Nox inhibitor and nfκb inhibitor containing methoxyflavoneInfo
- Publication number
- SG11201609248WA SG11201609248WA SG11201609248WA SG11201609248WA SG11201609248WA SG 11201609248W A SG11201609248W A SG 11201609248WA SG 11201609248W A SG11201609248W A SG 11201609248WA SG 11201609248W A SG11201609248W A SG 11201609248WA SG 11201609248W A SG11201609248W A SG 11201609248WA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor
- nox
- nfκb
- methoxyflavone
- containing methoxyflavone
- Prior art date
Links
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 title 1
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YEHDMSUNJUONMW-UHFFFAOYSA-N methoxyflavone Natural products COC1=CC=CC=C1C1=CC(=O)C2=CC=CC=C2O1 YEHDMSUNJUONMW-UHFFFAOYSA-N 0.000 title 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014097875 | 2014-05-09 | ||
| PCT/JP2015/063100 WO2015170683A1 (en) | 2014-05-09 | 2015-05-01 | Nox inhibitor and nfκb inhibitor containing methoxyflavone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201609248WA true SG11201609248WA (en) | 2016-12-29 |
Family
ID=54392533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609248WA SG11201609248WA (en) | 2014-05-09 | 2015-05-01 | Nox inhibitor and nfκb inhibitor containing methoxyflavone |
| SG10201808940WA SG10201808940WA (en) | 2014-05-09 | 2015-05-01 | Nox inhibitor and nfкb inhibitor containing methoxyflavone |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808940WA SG10201808940WA (en) | 2014-05-09 | 2015-05-01 | Nox inhibitor and nfкb inhibitor containing methoxyflavone |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170071902A1 (en) |
| JP (3) | JP6666837B2 (en) |
| KR (1) | KR20170002565A (en) |
| CN (1) | CN106456597A (en) |
| AU (1) | AU2015256997B2 (en) |
| CA (1) | CA2948127A1 (en) |
| SG (2) | SG11201609248WA (en) |
| TW (1) | TWI700278B (en) |
| WO (1) | WO2015170683A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017145221A (en) * | 2016-02-18 | 2017-08-24 | 株式会社レーネ | Tau protein aggregation inhibitor |
| JP6909559B2 (en) * | 2016-03-31 | 2021-07-28 | 株式会社アンチエイジングコミュニケーション | OPH activity enhancer |
| JP6462755B2 (en) * | 2017-04-04 | 2019-01-30 | 丸善製薬株式会社 | Brain function improving agent and food and drink for improving brain function |
| TWI646943B (en) * | 2017-12-08 | 2019-01-11 | 財團法人自行車暨健康科技工業研究發展中心 | Method for screening for muscular dysfunction through functional fitness |
| KR102032739B1 (en) * | 2018-01-31 | 2019-10-16 | 한림대학교 산학협력단 | Pharmaceutical composition for preventing and treating diabetic complications containing the novel chrysin derivative |
| CN110237066B (en) * | 2018-03-07 | 2022-03-29 | 上海市生物医药技术研究院 | Application of 3-methoxyflavone and derivatives thereof in preparation of medicines for treating or preventing nephropathy |
| CN108904489A (en) * | 2018-06-19 | 2018-11-30 | 杭州勃锐思莫生物医药科技有限责任公司 | The purposes of the preventing respiratory diseases associated with inflammation of 3,4 ' flavonol of 5,7- methoxyl group |
| JP7229513B2 (en) * | 2018-10-16 | 2023-02-28 | 丸善製薬株式会社 | Brain function improving agent and food and drink for improving brain function |
| CN109288834A (en) * | 2018-11-28 | 2019-02-01 | 武汉科技大学 | 5- methoxy flavone reads over the application in drug in preparation nonsense mutation |
| WO2020178267A1 (en) * | 2019-03-04 | 2020-09-10 | Universite D'aix-Marseille | Nox inhibitors for preventing epileptic seizures |
| CN110357846B (en) * | 2019-07-11 | 2021-06-15 | 上海健康医学院 | Flavone monoterpene compound and preparation method and application thereof |
| US20230021051A1 (en) * | 2019-12-26 | 2023-01-19 | Maruzen Pharmaceuticals Co., Ltd. | Composition Containing Black Ginger Extract and Composition for Oral Administration |
| CN111374970B (en) * | 2020-03-17 | 2023-05-30 | 广西壮族自治区中医药研究院 | Composition with anti-colitis activity and application thereof |
| CN111617076B (en) * | 2020-06-24 | 2021-09-28 | 江苏吴中医药集团有限公司 | Compound pharmaceutical composition containing arbidol hydrochloride and application thereof |
| JP7081843B2 (en) * | 2020-10-26 | 2022-06-07 | 株式会社東洋新薬 | Autonomic nerve regulator |
| WO2022137964A1 (en) * | 2020-12-23 | 2022-06-30 | 国立大学法人大阪大学 | Pharmaceutical composition for preventing or treating cartilage/bone/joint diseases, and method for screening drug for preventing or treating cartilage/bone/joint diseases |
| WO2023144742A1 (en) | 2022-01-26 | 2023-08-03 | Universidade De Aveiro | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005505506A (en) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | Macrocycles useful for the treatment of Alzheimer's disease |
| JP2007314468A (en) * | 2006-05-25 | 2007-12-06 | Meiji Milk Prod Co Ltd | Compound for controlling endoplasmic reticulum stress and pharmaceutical composition containing the compound as active component |
| JP2009051790A (en) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use |
| JP5756264B2 (en) * | 2010-05-06 | 2015-07-29 | 日本タブレット株式会社 | Xanthine oxidase inhibitor, xanthine oxidase and 5α-reductase inhibitor, and pharmaceutical composition containing the inhibitor |
| KR101811303B1 (en) * | 2011-07-26 | 2017-12-26 | 에스케이하이닉스 주식회사 | Semiconductor integrated circuit and method of driving the same |
| EP2799081A4 (en) * | 2011-12-27 | 2015-06-24 | Tokiwa Phytochemical Co Ltd | Sirtuin activator |
| JP2013144659A (en) * | 2012-01-16 | 2013-07-25 | Nippon Tablet Kk | 5α-REDUCTASE INHIBITOR AND FOOD, DRINK, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE INHIBITOR |
| WO2013172681A1 (en) * | 2012-05-16 | 2013-11-21 | 연세대학교 산학협력단 | Use of kaempferia parviflora wall. ex. baker extracts or flavone compound for preventing or treating muscle diseases, or improving muscle function |
| JP2013241354A (en) * | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | Phosphodiesterase 2 inhibitor |
| JP2013253047A (en) * | 2012-06-07 | 2013-12-19 | Kinki Univ | Hemorheology improving agent, and food and drink and pharmaceutical composition including the same |
| US9669003B2 (en) * | 2012-06-13 | 2017-06-06 | Yongri Jin | Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs |
-
2015
- 2015-05-01 CN CN201580024156.6A patent/CN106456597A/en active Pending
- 2015-05-01 US US15/308,868 patent/US20170071902A1/en not_active Abandoned
- 2015-05-01 WO PCT/JP2015/063100 patent/WO2015170683A1/en active Application Filing
- 2015-05-01 SG SG11201609248WA patent/SG11201609248WA/en unknown
- 2015-05-01 SG SG10201808940WA patent/SG10201808940WA/en unknown
- 2015-05-01 KR KR1020167034094A patent/KR20170002565A/en not_active Application Discontinuation
- 2015-05-01 JP JP2016517902A patent/JP6666837B2/en active Active
- 2015-05-01 CA CA2948127A patent/CA2948127A1/en not_active Abandoned
- 2015-05-01 AU AU2015256997A patent/AU2015256997B2/en not_active Ceased
- 2015-05-01 JP JP2015093939A patent/JP2015227329A/en active Pending
- 2015-05-06 TW TW104114409A patent/TWI700278B/en active
-
2019
- 2019-12-19 JP JP2019228987A patent/JP7015822B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2948127A1 (en) | 2015-11-12 |
| KR20170002565A (en) | 2017-01-06 |
| WO2015170683A1 (en) | 2015-11-12 |
| JP7015822B2 (en) | 2022-02-15 |
| AU2015256997B2 (en) | 2020-07-09 |
| AU2015256997A1 (en) | 2016-11-24 |
| SG10201808940WA (en) | 2018-11-29 |
| JP6666837B2 (en) | 2020-03-18 |
| JP2020063283A (en) | 2020-04-23 |
| JP2015227329A (en) | 2015-12-17 |
| CN106456597A (en) | 2017-02-22 |
| TW201625574A (en) | 2016-07-16 |
| JPWO2015170683A1 (en) | 2017-04-20 |
| US20170071902A1 (en) | 2017-03-16 |
| TWI700278B (en) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201609248WA (en) | Nox inhibitor and nfκb inhibitor containing methoxyflavone | |
| HK1243072A1 (en) | Bromodomain inhibitors and uses thereof | |
| IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| IL251051A0 (en) | Mk2 inhibitors and uses thereof | |
| FI3215147T3 (en) | Neuro-attenuating norketamine compounds and methods | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| PT3015526T (en) | Halo-olefin composition and use therefor | |
| IL251077A0 (en) | Integrin inhibitors and their use | |
| HK1243342A1 (en) | Compounds and methods | |
| HK1243077A1 (en) | Piperidinylpyrazolopyrimidinones and their use | |
| HK1250926A1 (en) | Inhibitors and their uses | |
| IL251078B (en) | Integrin inhibitors and their use | |
| HK1255029A1 (en) | Gelatinase inhibitors and use thereof | |
| IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
| IL247872A0 (en) | Stat5 inhibitors and use thereof | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| PL3229772T3 (en) | 6-aryl-9-glycosylpurines and use thereof | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201407599D0 (en) | New compounds and uses | |
| GB201407596D0 (en) | New compounds and uses | |
| GB201404335D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201404332D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201404330D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201402467D0 (en) | New Compounds and uses |